Pulmonary fibrosis is a disease
in which tissue deep inside the lungs becomes thick, stiff, and scarred,
decreasing the lungs’ ability to expand to take in air, and making it
difficult to breathe. This is a progressive disease in which scarring
and lack of elasticity in the lungs continues to increase until the
patient can no longer breathe enough to sustain life.
Until recently, patients in the U.S. suffering from idiopathic pulmonary fibrosis (IPF), a form of pulmonary fibrosis in which the cause is unknown, had no drug treatment approved by FDA for this debilitating, incurable, and terminal condition. However, this month, FDA approved Ofev (nintedanib) and Esbriet (pirfenidone), two important new therapies for the treatment of patients with IPF. Both drugs are “first-in-class” products that offer new hope for patients in the U.S. with IPF. Both the drugs are "first-in-class" products that offer new hope for patients in the U.S. with IPF.
For more information on the Drug Approval please CLICK HERE
Pulmonary
fibrosis is a disease in which tissue deep inside the lungs becomes
thick, stiff, and scarred, decreasing the lungs’ ability to expand to
take in air, and making it difficult to breathe. This is a progressive
disease in which scarring and lack of elasticity in the lungs continues
to increase until the patient can no longer breathe enough to sustain
life.
Until recently, patients in the U.S. suffering from idiopathic pulmonary fibrosis (IPF), a form of pulmonary fibrosis in which the cause is unknown, had no drug treatment approved by FDA for this debilitating, incurable, and terminal condition. However, this month, FDA approved Ofev (nintedanib) and Esbriet (pirfenidone), two important new therapies for the treatment of patients with IPF. Both drugs are “first-in-class” products that offer new hope for patients in the U.S. with IPF.
- See more at: http://blogs.fda.gov/fdavoice/index.php/2014/10/two-fda-drug-approvals-for-idiopathic-pulmonary-fibrosis-ipf/?source=govdelivery&utm_medium=email&utm_source=govdelivery#sthash.9IcHrO6z.dpuf
Until recently, patients in the U.S. suffering from idiopathic pulmonary fibrosis (IPF), a form of pulmonary fibrosis in which the cause is unknown, had no drug treatment approved by FDA for this debilitating, incurable, and terminal condition. However, this month, FDA approved Ofev (nintedanib) and Esbriet (pirfenidone), two important new therapies for the treatment of patients with IPF. Both drugs are “first-in-class” products that offer new hope for patients in the U.S. with IPF.
- See more at: http://blogs.fda.gov/fdavoice/index.php/2014/10/two-fda-drug-approvals-for-idiopathic-pulmonary-fibrosis-ipf/?source=govdelivery&utm_medium=email&utm_source=govdelivery#sthash.9IcHrO6z.dpuf
